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MaOBJECTIVES The aim of this study was to compare outcomes of alcohol septal ablation (ASA) in young and elderly
patients with obstructive hypertrophic cardiomyopathy (HCM).
BACKGROUND The American College of Cardiology Foundation/American Heart Association guidelines reserve ASA for
elderly patients and patients with serious comorbidities. Information on long-term age-specific outcomes after ASA is scarce.
METHODS This cohort study included 217 HCM patients (age 54  12 years) who underwent ASA because of
symptomatic left ventricular outflow tract obstruction. Patients were divided into young (age #55 years) and elderly
(age >55 years) groups and matched by age in a 1:1 fashion to nonobstructive HCM patients.
RESULTS Atrioventricular block following ASA was more common in elderly patients (43% vs. 21%; p ¼ 0.001),
resulting in pacemaker implantation in 13% and 5%, respectively (p ¼ 0.06). Residual left ventricular outflow tract
gradient, post-procedural New York Heart Association functional class, and necessity for additional septal reduction
therapy was comparable between age groups. During a follow-up of 7.6  4.6 years, 54 patients died. The 5- and 10-year
survival following ASA was 95% and 90% in patients age #55 years and 93% and 82% in patients age >55 years, which
was comparable to their control groups. The annual adverse arrhythmic event rate following ASA was 0.7%/year in young
patients and 1.4%/year in elderly patients, which was comparable to their control groups.
CONCLUSIONS ASA is similarly effective for reduction of symptoms in young and elderly patients; however, younger
patients have a lower risk of procedure-related atrioventricular conduction disturbances. The long-term mortality rate
and risk of adverse arrhythmic events following ASA are low, both in young and elderly patients, and are comparable to
age-matched nonobstructive HCM patients. (J Am Coll Cardiol Intv 2016;9:463–9) © 2016 by the American College of
Cardiology Foundation.m the aDepartment of Cardiology, St. Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands; bDepartment of Cardiol-
y, Martini Hospital, Groningen, the Netherlands; cDepartment of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotter-
m, the Netherlands; dDepartment of Cardiovascular Diseases, University of Leuven, Leuven, Belgium; and the eDepartment of
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ABBR EV I A T I ON S
AND ACRONYMS
AAE = adverse arrhythmic
event(s)
ASA = alcohol septal ablation





LVOT = left ventricular outflow
tract
LVWT = left ventricular wall
thickness
NYHA = New York Heart
Association
SCD = sudden cardiac death
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464I f patients with obstructive hypertrophiccardiomyopathy (HCM) remain severelysymptomatic despite optimal medical
therapy, septal reduction therapy should be
considered. This can be done either by surgi-
cal myectomy or alcohol septal ablation
(ASA) (1,2). ASA was introduced as a percuta-
neous alternative to surgical myectomy and
has been shown to be effective in reducing
left ventricular outflow tract (LVOT) obstruc-
tion and associated symptoms in the 20 years
since (3–5). Concerns about ASA remain, how-
ever, especially about the possible arrhyth-
mogenic effect of the ablation scar in
patients who are already at an increased risk
of life-threatening arrhythmias (6). The
American College of Cardiology Foundation/American Heart Association guidelines on HCM state
that ASA should be reserved for elderly patients and
patients with serious comorbidities (1). Little is known
about the differences in outcome of the procedure be-
tween young and elderly patients. The aim of this
study was to compare complication rates, symptom
relief, and long-term outcomes of ASA in young and
elderly patients.SEE PAGE 470METHODS
STUDY DESIGN AND PATIENT POPULATION. A
multicenter observational cohort design was used.
The study population consisted of 217 consecutive
HCM patients who underwent ASA in the St. Antonius
Hospital Nieuwegein, Nieuwegein, the Netherlands
(n ¼ 147), or the Thoraxcenter, Erasmus Medical
Center, Rotterdam, the Netherlands (n ¼ 70). All pa-
tients met the criteria for invasive treatment: 1)
ventricular septal thickness $15 mm; 2) (provocable)
LVOT gradient $50 mm Hg; and 3) persistent New
York Heart Association (NYHA) functional class III/IV
dyspnea or Canadian Cardiovascular Society class
III/IV angina despite optimal medical therapy (1,2).
The choice of ASA instead of surgical myectomy was
made on the basis of patient profile (age, comorbid-
ities, and so on) and patient preference. ASA was
performed as described previously (7,8). All patients
gave informed consent prior to the procedure. Local
institutional review board approval was obtained.
Patients were divided into groups by age: #55 and
>55 years. The cutoff of 55 years was chosen because
this was the median age of the study population
(range 18 to 80 years). For the long-term outcomes, 2
control groups were selected from a cohort of 349
nonobstructive HCM patients, also used as thecontrol group in a previous analysis (9). These pa-
tients, from the St. Antonius Hospital Nieuwegein,
Erasmus Medical Center Rotterdam, and University
Hospital Leuven (Belgium), all had an LVOT gradient
of <30 mm Hg after provocation. Control subjects
were matched by age to within 1 year of patients who
underwent ASA.
FOLLOW-UP AND ENDPOINTS. Follow-up started at
the time of ASA or, for the nonobstructive patients, at
first outpatient clinic contact after January 1, 1990. At
baseline, all patients were evaluated for the follow-
ing characteristics: age, sex, NYHA functional class,
maximum left ventricular wall thickness (LVWT),
maximum (provocable) LVOT gradient, left ventricu-
lar function, coronary artery disease, atrial fibrilla-
tion, and conventional risk factors for sudden cardiac
death (SCD) (1).
The primary endpoints of this study were all-cause
mortality and adverse arrhythmic events (AAEs)
during long-term follow-up (i.e., after 30 days post-
procedure). AAEs consisted of SCD, resuscitated
cardiac arrest due to ventricular fibrillation or tachy-
cardia, and appropriate implantable cardioverter-
defibrillator (ICD) shock. Secondary endpoints were
HCM-related death (death due to heart failure,
stroke, or SCD); periprocedural (<30 days) mortality
and AAEs; new right bundle branch block;
(temporary) atrioventricular block; permanent pace-
maker implantation; ICD implantation; reduction
in LVWT, LVOT gradient, and NYHA functional
class >3 months post-procedure; and reintervention
(ASA or myectomy).
Mortality and adverse events were retrieved from
hospital patient records at the center where follow-up
occurred, from civil service population registers, and
from information provided by patients themselves
and/or their general practitioners. All ICD shocks
were evaluated by an experienced electrophysiologist
who was unaware and independent of the study
purpose and endpoints. If no events occurred during
follow-up, the administrative censoring date was set
at November 1, 2012.
STATISTICAL ANALYSIS. SPSS version 20.0 (IBM,
Armonk, New York) and Microsoft Excel 2010
(Microsoft Corporation, Redmond, Washington) were
used for all statistical analyses. Categorical variables
were summarized as percentages. Normally distrib-
uted continuous data are expressed as mean  SD,
and non-normally distributed data are expressed as
median (interquartile range). To compare continuous
variables, the Student t test or Mann-Whitney U test
were used, and to compare categorical variables, the
chi-square test was used. Because age does not allow
TABLE 1 Baseline Characteristics of 107 Patients Age #55 Years and 110 Patients Age >55 Years Undergoing ASA and








(n ¼ 110) p Value
Comparison
p Value
Age, yrs 43  8 43  8 0.99 64  6 64  6 0.98 <0.001
Female 21 (20%) 30 (28%) 0.20 54 (49%) 39 (36%) 0.056 <0.001
NYHA functional class III/IV 90 (84%) 9 (8%) <0.001 84 (76%) 18 (16%) <0.001 0.21
Maximum LVWT, mm 20  6 18  5 <0.001 19  4 18  5 0.17 0.001
Maximum LVOT gradient, mm Hg 65  56 6  5 <0.001 60  63 7  5 <0.001 0.68
Systolic dysfunction (EF <50%) 2 (2%) 15 (14%) 0.002 10 (9%) 25 (23%) 0.010 0.042
Coronary artery disease 8 (8%) 12 (11%) 0.48 37 (34%) 18 (16%) 0.005 <0.001
Atrial fibrillation 20 (19%) 29 (27%) 0.19 26 (24%) 47 (43%) 0.004 0.47
Sudden cardiac death survivor 4 (4%) 8 (8%) 0.38 2 (2%) 11 (10%) 0.022 0.44
$2 conventional risk factors for SCD 16 (15%) 16 (15%) 1.0 9 (8%) 22 (20%) 0.020 0.18
Amount of alcohol, ml 3.0 (1.0) — — 2.0 (1.0) — — 0.013
Values are n (%), mean  SD, or median (interquartile range).
ASA ¼ alcohol septal ablation; EF ¼ ejection fraction; LVOT ¼ left ventricular outflow tract; LVWT ¼ left ventricular wall thickness; NYHA ¼ New York Heart Association;
SCD ¼ sudden cardiac death.
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465for exact matching, analyses were performed on in-
dependent groups. Kaplan-Meier graphs were used to
show survival rates. In all analyses, a p value <0.05
was considered significant.TABLE 2 Procedural Outcomes After Alcohol Septal Ablation in 107 Patients







Periprocedural (<30 days) complications
New right bundle branch block 42 (39%) 39 (36%) 0.66
(Temporary) atrioventricular block 22 (21%) 47 (43%) 0.001
Permanent pacemaker implantation 5 (5%) 14 (13%) 0.063
ICD implantation 15 (14%) 11 (10%) 0.48
Adverse arrhythmic events 8 (8%) 8 (7%) 1.0
Mortality 2 (2%) 0 (0%) 0.24
Procedure efficacy
Residual LVWT >3 months post-procedure, mm 14  5 14  4 0.45
Residual LVOT gradient >3 months
post-procedure, mm Hg
12  27 10  27 0.99
Reduction in LVOT gradient >3 months
post-procedure, %
78  60 76  60 0.68
NYHA functional class III/IV >3 months
post-procedure
5 (5%) 9 (9%) 0.43
Redo septal reduction therapy 14 (13%) 13 (12%) 0.94
Values are n (%) or mean  SD.
ICD ¼ internal cardioverter defibrillator; other abbreviations as in Table 1.RESULTS
CLINICAL CHARACTERISTICS. The baseline charac-
teristics of the 217 patients who underwent ASA and
their age-matched control subjects are shown in
Table 1. The mean age of the patients #55 years was
438 years, and themean age of the patients>55 years
was 64  6 years. There were more nonobstructive
patients with systolic dysfunction compared with
patients who underwent ASA. A higher alcohol dose
was used for ASA in patients age #55 years compared
with patients age >55 years (p ¼ 0.013).
PROCEDURAL OUTCOMES. Procedural outcomes of
the patients who underwent ASA are shown in Table 2.
Atrioventricular block following ASA was more com-
mon in patients age >55 years compared with patients
age #55 years (43% vs. 21%; p ¼ 0.001), resulting in
permanent pacemaker implantation in 13% and 5%,
respectively (p ¼ 0.06). Other periprocedural compli-
cations, including AAEs and mortality, were similar in
both groups. Residual LVWT, LVOT gradient, and
NYHA functional class >3 months post-procedure
were comparable in both age groups, as was the ne-
cessity for additional septal reduction therapy.
LONG-TERM OUTCOMES. During a mean follow-up of
7.6  4.6 years, there were a total of 20 deaths in the
ASA cohorts and 34 deaths in the control groups
(Tables 3 and 4). Follow-up was complete in 98%
of patients. The 5- and 10-year survival following ASAof patients age #55 years was 94.9% (95% confidence
interval [CI]: 90.4% to 100.0%) and 90.2% (95% CI:
82.2% to 98.1%), respectively, compared with 98.0%
(95% CI: 95.4% to 100.0%) and 88.1% (95% CI: 80.1%
to 96.1%) in the control group (p ¼ 0.87) (Figure 1).
The 5- and 10-year survival following ASA of patients
age >55 years was 93.2% (95% CI: 88.0% to 98.5%)
and 81.9% (95% CI: 71.8% to 91.9%), respectively,
compared with 91.7% (95% CI: 86.1% to 97.3%) and
82.7% (95% CI: 72.9% to 92.6%) in the control group
(p ¼ 0.51) (Figure 2). The annual AAE rate following
ASA in patients age #55 years was 0.7%/year
compared with 1%/year in the control group (p ¼ 0.6).
FIGURE 1 Kaplan-Meier Graph of All-Cause Survival in
Patients Age #55 Years Who Underwent ASA Versus
Age-Matched Nonobstructive HCM Patients
ASA ¼ alcohol septal ablation; HCM ¼ hypertrophic
cardiomyopathy.
FIGURE 2 Kaplan-Meier Graph of All-Cause Survival in
Patients Age >55 Years Who Underwent ASA Versus
Age-Matched Nonobstructive HCM patients
Abbreviations as in Figure 1.
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466The annual AAE rate following ASA in patients age
>55 years was 1.4%/year compared with 0.5%/year in
the control group (p ¼ 0.07).
DISCUSSION
The most important result of this 7.6-year follow-up
study is that long-term survival following ASA in
young and elderly patients is comparable to survival
in age-matched nonobstructive HCM patients, and
the same holds true for AAE rates. Furthermore, ASA
is similarly effective for reduction of symptoms in
young and elderly patients, although younger pa-
tients have a lower risk of procedure-related atrio-
ventricular conduction disturbances.
PREVIOUS AGE-SPECIFIC ASA STUDIES. Currently, in-
formation on the long-term age-specific outcomes
after ASA in patients with obstructive HCM is scarce.
Two previous studies (10,11) have evaluated age-
specific outcomes of ASA patients during a follow-
up period of 1 and 5.1 years, respectively. Leonardi
et al. (10) compared the outcomes of 360 HCM pa-
tients undergoing ASA in 3 age categories (<45, 45 to
64, and >65 years). Likewise, they found that the
reductions in LVOT gradient and NYHA functional
class following ASA were similar independent of age
and that elderly patients more often required pace-
maker implantation after the procedure. There were
no control groups, however, and not surprisingly, the
mortality rate after a follow-up of 1 year was highest
in patients age >65 years. Veselka et al. (11) assessed
the 5.1-year outcomes following ASA in 75 patients
age 42  7 years, which is comparable to the mean age
of our young patients. They found a survival free of
all-cause mortality at 5 and 10 years of 94% each,which is in line with our findings. No comparisons
with elderly patients were made, however.
CURRENT GUIDELINES. The American College of
Cardiology Foundation/American Heart Association
guidelines on HCM of 2011 state that ASA should be
reserved for elderly patients and patients with
serious comorbidities, and gives a Class III recom-
mendation (Level of Evidence: C) to ASA for younger
patients if myectomy is a viable option (1). The pro-
cedural mortality rate is reported to be <1% for
myectomy versus up to 4% for ASA (1,12–14). Larger,
more recent ASA studies have shown rates of 0.3% to
0.6%, however (15,16). Also, a recent meta-analysis
comparing ASA to myectomy showed similarly low
periprocedural and long-term mortality rates (17).
Furthermore, subsequent to the publication of the
2011 guidelines, the post-ASA prognosis was demon-
strated to be comparable with the sex- and age-
matched population (15,16,18) and with matched
post-myectomy patients (18). Notably, these and
other studies (15,16,19) showed that age was the only
independent predictor of mortality following ASA,
implying that survival in patients after ASA is not
determined by ASA, but by HCM itself.
One of the main concerns about ASA in younger
patients is the potential arrhythmogenic effect of
the ablation scar in patients who are already at an
increased risk of life-threatening arrhythmias (6).
Recent studies have shown, however, that the long-
term risk of SCD after ASA is low and comparable to
patients who undergo myectomy (9,17,18). This study
showed an annual AAE rate following ASA of 0.7%/
year in the young patients, which was similar to age-
matched nonobstructive HCM patients and one-half
the rate of elderly patients.
TABLE 3 Long-Term Outcomes After Alcohol Septal Ablation in










Follow-up, yrs 7.2  3.4 9.2  5.6
Mortality (>30 days post-procedure)
Total mortality 5 (5%) 15 (14%) 0.036
HCM-related death 3 (3%) 11 (10%) 0.055
Noncardiac 2 (2%) 4 (4%) 0.68
5-yr survival, % 95 98 0.87
10-yr survival, % 90 88 0.87
Adverse arrhythmic events (>30 days post-procedure)
Total adverse events 5 (5%) 9 (8%) 0.41
Sudden cardiac death 2 (2%) 4 (4%) 0.68
Resuscitated cardiac arrest 1 (1%) 2 (2%) 1.0
Appropriate ICD shocks 2 (2%) 3 (3%) 1.0
Annual events, %/yr 0.7 1.0 0.58
Values are mean  SD or n (%). ASA ¼ alcohol septal ablation; HCM ¼ hyper-
trophic cardiomyopathy; ICD ¼ internal cardioverter defibrillator.
TABLE 4 Long-Term Outcomes After Alcohol Septal Ablation in 107 Patients




(n ¼ 110) p Value
Follow-up, yrs 6.5  3.8 7.5  4.8
Mortality (>30 days post-procedure)
Total mortality 15 (14%) 19 (17%) 0.58
HCM-related death 4 (4%) 10 (9%) 0.17
Noncardiac 11 (10%) 8 (7%) 0.63
5-yr survival, % 93 92 0.51
10-yr survival, % 82 83 0.51
Adverse arrhythmic events (>30 days post-procedure)
Total adverse events 10 (9%) 4 (4%) 0.17
Sudden cardiac death 3 (3%) 0 (0%) 0.25
Resuscitated cardiac arrest 2 (2%) 1 (1%) 1.0
Appropriate ICD shocks 5 (5%) 3 (3%) 0.72
Annual events, %/yr 1.4 0.5 0.070
Values are mean  SD or n (%). Abbreviations as in Table 3.
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467Another conceivable reason to choose myectomy
instead of ASA in younger patients is the >2 higher
risk of atrioventricular block requiring pacemaker
implantation following ASA (17,20). This higher need
for pacemaker implantation may at least partly be
explained by the higher age of the patients under-
going ASA: the ASA patients from both meta-analyses
were on average 9 years older than the myectomy
patients. The present and previous studies have
shown that atrioventricular conduction disturbances
following ASA are mainly seen in elderly patients
(10,21), with a need for pacemaker implantation in
only 5% of the young patients, despite a higher
amount of alcohol use in the young patients. Large
outcome studies following myectomy in HCM patients
of similar age categories (mean age 37 to 47 years)
showed incidences of atrioventricular block requiring
pacemaker implantation of 1% to 6% (12,13,22,23).
Because the improvement in functional status
following ASA in young and elderly patients is simi-
larly good, we propose that the indication for ASA can
be broadened to younger patients. In other words,
younger age alone should not be a reason to exclude
ASA. For children and adolescents, however, little to
no results are available following ASA, although there
is substantial experience with myectomy (24). We
therefore recommend against ASA in this age group
until studies have proven the safety and efficacy of the
procedure in these very young patients.
PATIENT SELECTION AND SPECIALIZED CARE. In
line with the 2011 American College of Cardiology (1)and the 2014 European Society of Cardiology (2)
guidelines, we recommend that all patients consid-
ered for septal reduction therapy are assessed by a
multidisciplinary heart team (consisting of at least 1
cardiothoracic surgeon, an interventional cardiolo-
gist, and a cardiologist specialized in the care of pa-
tients with HCM) to determine the optimal therapy by
taking into account not only age, but also factors such
as mitral valve anatomy, coronary anatomy, septal
thickness, and comorbidities. When both procedures
are possible, shared decision making between the
informed patient and treating physician should also
be part of the equation. Furthermore, septal reduc-
tion therapy should be performed by experienced
operators and confined to centers with substantial
and specific expertise in HCM care.
STUDY LIMITATIONS. There were significant differ-
ences in baseline characteristics between the young
and elderly patients who underwent ASA. Besides
the expected differences in prevalence of systolic
dysfunction and coronary artery disease, we noted
higher amounts of alcohol use in the age #55 years
population. The same also held true in a recent study
comparing the use of low (#2 ml) versus high (>2 ml)
doses of alcohol for ASA (25). In this study of the same
patient population as the present study, patients
from the high-dose group were significantly younger
than those from the low-dose group. Although the 2
groups did not differ in maximal LVWT or LVOT
gradient, the patients from the high-dose group did
have larger target septal perforator(s), which might
explain the difference.
This study has several other limitations. The
study was performed in tertiary referral centers for
PERSPECTIVES
WHAT IS KNOWN? The American College of Car-
diology Foundation/American Heart Association
guidelines reserve ASA for elderly patients and pa-
tients with serious comorbidities. Information on
long-term age-specific outcomes after ASA is scarce.
WHAT IS NEW? We found that ASA is similarly
effective for reduction of symptoms in young and
elderly patients and that the long-term mortality rate
and risk of AAEs following ASA in young and elderly
patients is comparable to age-matched nonobstruc-
tive HCM patients.
WHAT IS NEXT? We propose that the indication for
ASA can be broadened to younger patients. However,
more studies with long-term follow-up of young HCM
patients undergoing ASA are warranted to confirm
these findings.
Liebregts et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 5 , 2 0 1 6
Outcome of ASA in the Young and the Elderly M A R C H 1 4 , 2 0 1 6 : 4 6 3 – 9
468the care of HCM, and the patient population might
not represent the general HCM population. This
referral and selection bias could have influenced
the results. Data collection was limited to variables
that were routinely collected. We did not cor-
rect for individual or local alterations of percuta-
neous technique. However, all procedures were
performed by experienced interventional cardio-
logists, and this implies that our findings are
more generalizable than those of single-center
investigations.
CONCLUSIONS
ASA is similarly effective for reduction of symptoms
in young and elderly patients; however, younger
patients have a lower risk of procedure-related
atrioventricular conduction disturbances. The long-
term mortality rate and risk of AAEs following ASA
is low, both in young and elderly patients, and is
comparable to age-matched nonobstructive HCM
patients. We propose that the indication for ASA
can be broadened to younger patients.
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